Oncopeptides AB (FRA:OND) Tax Provision: €-0.14 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OND Oncopeptides AB FRA:OND
34 GF Score
Price €0.14
GF Value €0.39
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB Tax Provision?

Oncopeptides AB FRA:OND +0.85% 34 Tax Provision is €-0.14 Mil as of Mar. 2026. GuruFocus rates FRA:OND with a GF Score™ of 34/100 and a GF Value™ of €0.39 (Possible Value Trap). The stock has 3 warning signs investors should review.

Oncopeptides AB's tax provision for the three months ended in Mar. 2026 was €-0.01 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.14 Mil.

Oncopeptides AB Tax Provision Historical Data

* Premium members only.

The historical data trend for Oncopeptides AB's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncopeptides AB Tax Provision Chart

Oncopeptides AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.87 -0.03 -0.06 -0.04 -0.13

Oncopeptides AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.01 -0.11 -0.01
FRA:OND
34GF Score
Oncopeptides AB FRA:OND
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncopeptides AB Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of €-0.14 Mil mean?
Oncopeptides AB (FRA:OND) has a Tax Provision of €-0.14 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Oncopeptides AB and its competitors.
Is Oncopeptides AB's Tax Provision too high?
Oncopeptides AB's current Tax Provision is €-0.14 Mil. Overall, Oncopeptides AB has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Tax Provision compare to VRTX and REGN?
Oncopeptides AB's Tax Provision of €-0.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current Tax Provision is €-0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.39, compared to a current price of €0.14 — trading 63.3% below its estimated fair value. The current Tax Provision is €-0.14 Mil. Oncopeptides AB's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current Tax Provision is €-0.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncopeptides AB (FRA:OND) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of €0.14 is trading 63.3% below its estimated GF Value™ of €0.39. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for FRA:OND:

  • Tax Provision: €-0.14 Mil
  • GF Value™: €0.39 vs. price of €0.14 (63.3% below fair value)
  • GF Score™: 34/100 with 3 warning signs

No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncopeptides AB Business Description

Other Exchanges ONCO:SwedenONCOs:UK0RN4:UK
Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
34GF Score

Get the complete analysis for FRA:OND

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.39
GF Value